The traditional diet of Greece and cancer.

R.B. · 08-20-2007, 04:11 PM

The first trial you have seen before I think the rest a new here.

Just in case you have lost sight of the omega threes and sixes

RB

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"These findings reveal that the omega-3 PUFA ALA suppresses overexpression of HER2 oncogene at the transcriptional level, which, in turn, interacts synergistically with anti-HER2 trastuzumab- based immunotherapy. ii) Our results molecularly support a recent randomized double-blind placebo-controlled clinical trial suggesting that ALA may be a potential dietary alternative or adjunct to currently used drugs in the management of HER2-positive breast carcinomas. iii) Considering our previous findings demonstrating the HER2 upregulatory actions of the omega-6 PUFA linolenic acid (LA; 18:2n-6) and the HER2 down-regulatory actions of the omega-3 PUFA docosahexaenoic acid (DHA; 22:6n-3) and of the omega-9 monounsaturated fatty acid oleic acid (OA; 18:1n-9), it is reasonable to suggest that a low omega-6/omega-3 PUFA ratio and elevated MUFA levels, the two prominent fat features of the Mediterranean diet, should be extremely efficient at blocking HER2 expression in breast cancer cells."

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"our results indicate that (n-3) FA modify the lipid composition of membrane rafts and alter EGFR signaling in a way that decreases the growth of breast tumors."

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"Use of canola oil instead of corn oil in the diet may be a reasonable means to increase consumption of n-3 fatty acids with potential significance for slowing growth of residual cancer cells in cancer survivors."

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"In conclusion, we showed that erythrocyte compositions of specific fatty acids derived from fish intake, as biomarkers, are associated with lower risk of breast cancer, but further studies are needed to investigate mechanisms linked to the etiology. (c) 2007 Wiley-Liss, Inc."

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"Since DHA influences the product of a major tumour suppressor gene, this finding may contribute to the observation that high-fish consumption reduces the risk of breast cancer."

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

"Our results support the premise that DHA and genistein exert complementary actions whilst genistein is antagonistic to AA for controlling PGE(2) production as well as invasiveness of MDA-MB-231 cells in culture by modulating the level of NFkappaB expression."

R.B. · 09-06-2007, 11:00 AM

Just bumping this up and adding a few bits I came across by accident whilst looking for something else.

RB

CoQ10.

Very small numbers and not much detail but thought provoking.

Views on CoQ10 vary amongst oncologists so please discuss any supplementation with your advisor.

I simply seek to inform options.

RB

1: Clin Biochem. 2000 Jun;33(4):279-84.Click here to read Links
Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients.
Portakal O, Ozkaya O, Erden Inal M, Bozan B, Koşan M, Sayek I.

Department of Biochemistry, The Medical School of Osmangazi University, Eskişehir, Turkey. portakal@ada.net.tr

OBJECTIVES: An increasing amount of experimental and epidemiological evidence implicates the involvement of oxygen derived radicals in the pathogenesis of cancer development. Oxygen derived radicals are able to cause damage to membranes, mitochondria, and macromolecules including proteins, lipids and DNA. Accumulation of DNA damages has been suggested to contribute to carcinogenesis. It would, therefore, be advantageous to pinpoint the effects of oxygen derived radicals in cancer development. DESIGN AND METHODS: In the present study, we investigated the relationship between oxidative stress and breast cancer development in tissue level. Breast cancer is the most common malignant disease in Western women. Twenty-one breast cancer patients, who underwent radical mastectomy and diagnosed with infiltrative ductal carcinoma, were used in the study. We determined coenzyme Q10 (Q) concentrations, antioxidant enzyme activities (mitochondrial and total superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), catalase), and malondialdehyde (MDA) levels in tumor and surrounding tumor-free tissues. RESULTS: Q concentrations in tumor tissues significantly decreased as compared to the surrounding normal tissues (p < 0.001). Higher MDA levels were observed in tumor tissues than noncancerous tissues (p < 0.001). The activities of MnSOD, total SOD, GSH-Px and catalase in tumor tissues significantly increased (p < 0.001) compared to the controls. CONCLUSIONS: These findings may support that reactive oxygen species increased in malignant cells, and may cause overexpression of antioxidant enzymes and the consumption of coenzyme Q10. Increased antioxidant enzyme activities may be related with the susceptibility of cells to carcinogenic agents and the response of tumor cells to the chemotherapeutic agents. Administration of coenzyme Q10 by nutrition may induce the protective effect of coenzyme Q10 on breast tissue.

PMID: 10936586 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.
Lockwood K, Moesgaard S, Yamamoto T, Folkers K.

Pharma Nord, Vejle, Denmark.

Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer, which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years. The numerous metastases in the liver of a 44-year-old patient "disappeared," and no signs of metastases were found elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q10, revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.83-0.97 and of 0.62 micrograms/ml increased to 3.34-3.64 and to 3.77 micrograms/ml, respectively, on therapy with CoQ10 for patients A-MRH and EEL.

PMID: 7612003 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

1: Biochem Biophys Res Commun. 1994 Mar 30;199(3):1504-8.Click here to read Links
Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.
Lockwood K, Moesgaard S, Folkers K.

Pharma Nord, Vejle, Denmark.

Relationships of nutrition and vitamins to the genesis and prevention of cancer are increasingly evident. In a clinical protocol, 32 patients having -"high-risk"- breast cancer were treated with antioxidants, fatty acids, and 90 mg. of CoQ10. Six of the 32 patients showed partial tumor regression. In one of these 6 cases, the dosage of CoQ10 was increased to 390 mg. In one month, the tumor was no longer palpable and in another month, mammography confirmed the absence of tumor. Encouraged, another case having a verified breast tumor, after non-radical surgery and with verified residual tumor in the tumor bed was then treated with 300 mg. CoQ10. After 3 months, the patient was in excellent clinical condition and there was no residual tumor tissue. The bioenergetic activity of CoQ10, expressed as hematological or immunological activity, may be the dominant but not the sole molecular mechanism causing the regression of breast cancer.

PMID: 7908519 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum

1: Biochem Biophys Res Commun. 1997 May 19;234(2):296-9.Click here to read Links
Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer.
Folkers K, Osterborg A, Nylander M, Morita M, Mellstedt H.

Institute for Biomedical Research, University of Texas at Austin, 78712, USA.

New data on blood levels of vitamin Q10 in 116 cancer patients reveal an incidence of 23.1% of patients (N=17) with breast cancer whose blood levels were below 0.5 microg/ml. The incidence of breast cancer cases with levels below 0.6 microg/ml was 38.5%. The incidence is higher (p<0.05) than that for a group of ordinary people. Patients (N=15) with myeloma showed a mean blood level of 0.67 +/- 0.17 microg/ml. The incidence of a vitamin Q10 blood level below 0.7 microg/ml for these 15 cases of myeloma was 53.3%, which is higher (p<0.05) than the 24.5% found for a group of ordinary people.

PMID: 9177262 [PubMed - indexed for MEDLINE]